Drug Trial Radar · NCT03537482
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
90
Planned (sponsor's estimate)
Start
Aug 7, 2018
Primary completion
Sep 15, 2024
Study completion Feb 15, 2025
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2018
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
Conditions
- Hematologic Malignancies
Interventions
APG-2575Drug
APG-2575 will be administered as an oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: 28 days
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Jacksonville, Florida · Recruiting
Duke Unviersity
Durham, North Carolina · Completed
MDACC
Houston, Texas · Recruiting
St. Vincent Hospital
Fitzroy, Victoria, Australia · Recruiting
Epworth Healthcare
Richmond, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.